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Abstract 
 
Recent Advances and Challenges in  
Antigen Engineering & Vaccine Development 
 
William Joseph Kornahrens, Jr., M.S.E. 
The University of Texas at Austin, 2014 
 
Supervisor:  Jennifer Maynard 
 
Vaccines play a vital role in public health by preventing infectious disease across 
the globe. Vaccine formulations represent a weakened form of a microbe or toxin that is 
injected into the human body to elicit an immune response, generating antibodies to 
protect against a future infection. To this day, it is a challenge to identify and engineer 
important antigens and epitopes to focus this immune response in a safe and effective 
manner. The example of Bordetella pertussis is used to highlight the problems and 
lessons learned in designing a vaccine for this global epidemic. In particular, this review 
will focus on the advantages and disadvantages of chemical versus genetic detoxification 
and whole cell versus acellular vaccines in the context of pertussis. The latter part of this 
review will provide a summary of general strategies, such as epitope mapping and 
manipulation, synthesis of truncated variants, reverse vaccinology, and structural 
vaccinology, that have been successful in addressing increasingly complex diseases. 
Collectively, these techniques provide an invaluable set of tools to focus the immune 
response by finding and engineering specific antigens and epitopes. 
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 1 
Introduction 
One of the main goals of modern medicine is the prevention of infection before it 
occurs, especially for incurable diseases. Historically, one of the most effective ways of 
accomplishing this goal is through the use of vaccines. In 1796, it was Edward Jenner 
who introduced the concept of isolating cowpox, a naturally weakened form of smallpox 
in humans, and injecting it in order to induce protection.1 Later on, Louis Pasteur 
conducted experiments that famously proved microorganisms were the cause of 
infections, and developed the “rules” by which one could prepare a vaccine: isolate, 
inactivate, and inject the microorganism. This strategy led to the development of many 
different vaccines, reducing the mortality rates for infectious diseases such as smallpox, 
polio, measles, and many others across the globe. Some diseases have been nearly or 
completely eliminated due to effectiveness of the protection and widespread use. 
 While it is undeniable that vaccines have had tremendous success from a public 
health perspective, there have been many unexpected challenges in vaccine development. 
It is inefficient and potentially hazardous to use the entire microorganism in a vaccine 
rather than specific antigens or epitopes for a targeted response that is more effective. 
Many issues must be addressed to identify, design, and produce immunogens so that they 
are safe, effective, and economical. First, this review will focus on these problems in the 
context of the development of pertussis vaccine, followed by short-term solutions that 
have been tried. The review will then conclude with an overview of general problems for 
vaccine development in a wide variety of diseases and discuss past and current strategies 
that are crucial for solving them. 
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Acellular Vaccines – the Pertussis Example 
The very first pertussis vaccine was based on the vaccine ideas first introduced by 
Edward Jenner, in that the microbe Bordetella pertussis was chemically treated with 
formaldehyde and then used to make what would be known as the whole cell pertussis 
(wP) vaccine. However, this vaccine has been linked to inducing encephalopathy in mice, 
and these effects are speculated to occur in genetically susceptible patients as well.2 
These dangerous side effects and risks, though far outweighed by the benefits of wP, 
were part of the reason that there was a movement to develop a safer vaccine. One 
approach that may limit the potential for adverse reactions is to target specific, 
recognizable components of the microbe or its toxic products. This is useful from the 
practical standpoint of not having to grow cultures and process them for safety and 
purification. It can also be advantageous to concentrate the immune response on only the 
critical components needed for effective neutralization or protection.  
The acellular pertussis (aP) vaccine was developed based on the idea that only 
specific detoxified antigens were needed to induce an immune response. The S1 subunit 
of pertussis toxin (PTx) was discovered to be the subunit primarily responsible for 
toxicity while subunits S2 through S5 were functionally used for transport and invasion 
of host cells. To this day, it is common to combine chemically inactivated PTx with 
formalin-inactivated diphtheria and tetanus toxins all into one TdaP (tetanus, diphtheria, 
and acellular pertussis) vaccine. Additional antigens that have been included to induce 
immunity to pertussis include filamentous hemagglutinin (FHA) and pertactin (PRN). 
Five-component vaccine formulations include the fimbrial proteins 2 and 3 (FIM2 and 
FIM3), which are virulence factors known to mediate binding of the bacterial cells to the 
lung tissue. The two vaccines currently used in the US have PTx, FHA, and PRN, either 
with or without FIM2 and FIM3. 
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Problems with Acellular Pertussis Vaccine 
Unfortunately, the setbacks with the acellular pertussis vaccine provide a useful 
illustration of the many challenges that must be faced in vaccine development. Several 
studies have found indications that the DTaP vaccine does not confer long lasting 
immunity when compared to a previous whole cell vaccine in which the entire Bordetella 
pertussis microbe was chemically treated with formaldehyde. Ever since the acellular 
vaccine was introduced to the US, the number of pertussis cases has been steadily on the 
rise, as shown in Figure 1. In 2010, California experienced an outbreak of 9,000 pertussis 
cases and 10 infant deaths.3 The Center for Disease Control and Prevention (CDC) 
reported that the data collected during this outbreak suggested that vaccine effectiveness 
was about 98% during the first year after the fifth dose of aP vaccine but declines each 
year, down to 71% after five years.3 This trend is not limited to the US, as France, Italy, 
Japan, Finland, and other countries that recently distributed the acellular vaccine have 
reported a continuously increasing number of pertussis cases each year.  
 
Figure 1. Reported Cases to the CDC between 1922 to 2012.3 DTP is another 
name for whole cell vaccine, DTaP is the acellular vaccine, and Tdap is the 
acellular vaccine with a reduced level of diphtheria toxoid. 
 
Mutations to Evade Neutralization 
In 2012, there were 42,000 cases of pertussis in the US, making pertussis the most 
common vaccine-preventable illness in the country. There has been much speculation on 
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possible hypotheses to explain why pertussis is reemerging. One possibility is that B. 
pertussis may be evolving and slowly adapting to the challenge and selection set forth by 
the acellular vaccine. It is possible that mutations in the genes for the antigens contained 
in aP may be a way for B. pertussis to adapt and survive in humans who have received 
the vaccine. There is evidence that this has already occurred in France and Finland for the 
antigen PRN, which is thought to be an important adhesion used by the bacterium for 
attaching to epithelial cells.4 After aP was administered in these countries, B. pertussis 
strains lacking the expression of PRN became more prevalent, and studies examining 
macrophage cytotoxicity and the murine model of infection have shown these strains to 
be just as lethal as the strains that do express PRN.5 One study found that strains 
expressing a combination of the prn2-ptxP3 alleles were the most prevalent during an 
epidemic in Australia. This was explained by previous evidence indicating that the prn2 
allele had been shown to confer an advantage to selective pressure from the acellular 
vaccine while the ptxP3 allele was associated with higher hospitalization and mortality 
rates due to increased production of pertussis toxin.6 An additional study that examined 
changes in pertussis strains during a 2008-2010 Japanese pertussis epidemic found that 
strains expressing the fim3B mutation increased dramatically during this time frame 
while strains that did not express PRN were decreased by half.7 These facts indicate that 
strains expressing the fim3B mutation may have been the more likely cause of this 
particular epidemic in Japan. 
Memory T-cell Responses 
Another factor that could possibly contribute to the recent uptick in pertussis 
cases could be the skewing of the immune response in children. While aP is very 
effective at eliciting a strong response to the antigens contained in the vaccine, this may 
not be as effective in the long run as the whole cell vaccine’s induction of a broad 
adaptive response to many antigens simultaneously. Adaptive immunity is determined in 
large part by Th1 and Th2 responses. CD4+ T-cell helpers are important in mediating and 
coordinating the immune response. Several studies have shown that infant immunization 
with aP results in a skewed Th2 response and relatively weak Th1 response, which puts 
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the children at a long-term disadvantage with regard to cellular memory immune 
responses to pertussis.8 This contrasts with the wP vaccine which elicits a generally 
weaker response to a larger variety of antigens.  
Recent evidence has shown that Th17 is important in recruiting neutrophils at 
mucosal surfaces to control extracellular bacterial infections. Warfel et al. studied the 
responses of infant baboons immunized with aP, wP, or neither at 2, 4, and 6 months and 
challenged with pertussis at 7 months.9 One unique aspect of this study is that the 
common method of transmission in humans by coughing is preserved in this animal 
model of disease. They found that, while aP and wP induced high levels of response to 
the antigen components and pertussis symptoms were reduced, this did not prevent 
transmission and colonization of the disease in naïve baboons, as measured by 
nasopharyngeal washes. A separate part of the study measured cytokine responses in 
fractions of peripheral blood mononucleated cells incubated ex vivo with heat-treated B. 
pertussis in order to identify the associated memory T-cell responses. They found that the 
T-cell responses were different in that aP resulted in Th1/Th2 while wP induced Th17 
and Th1 memory responses, which more closely matched the responses by individuals 
with previous natural infection. They concluded that this difference in response was an 
indication that the aP response is mismatched to the disease and that more research needs 
to be done to determine how Th17/Th1 responses are stimulated and more effort should 
be made to produce vaccines that match these responses. 
Chemical and Genetic Inactivation 
The initial method for detoxifying antigens generally involved incubating them in 
chemicals such as formaldehyde, glutaraldehyde, hydrogen peroxide, and various other 
chemicals. Like many of the best discoveries, this method was developed by complete 
accident when Gaston Ramon had decided to store the culture supernatant of 
Corynebacterium diphtheriae in formaldehyde to help prevent contamination.10 He later 
discovered that prolonged storage in formaldehyde resulted in the loss of the toxin’s 
ability to kill animals and conferred resistance to future injections of the toxin. 
Formaldehyde is very popular and has been used in the chemical detoxification of tetanus 
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and pertussis toxins for vaccine development. Unfortunately, chemical detoxification is 
not always ideal since it has been shown to cause reduced immunogenicity and residual 
toxin activity as a result of changes in the antigen’s conformation. In addition, the 
chemical detoxification could lead to large batch variability and expensive testing to 
ensure that the toxoid would not revert back to a potent toxin.  
The main concept behind genetic inactivation of toxins is to make mutations and 
then select for the mutant versions that offer the best immunogenicity and lowest toxicity. 
For example, the National Institute of Allergy and Infectious Diseases (NIAID) produced 
genetically inactivated forms of PTx.11 Later, clinical trials by Podda et al. and others 
found that the 9K/129G PTx mutant (Arg-9àLys and Glu-129àGly) was both safe and 
immunogenic in children and infants, making it an ideal candidate for a new vaccine.12 
Furthermore, NIAID studies showed that vaccines with 5-10 ug of PTx mutant produced 
the same or higher levels of IgG anti-PT as 25 ug of chemically detoxified PTx, which 
suggests that the mutant PTx is five times as immunogenic and would confer immunity 
for a longer period of time.13 Despite the potential benefits of using the new genetically 
detoxified antigens, patents and excessive costs for testing have deterred vaccine 
manufacturers from pursuing the production of the genetically modified version of PTx.  
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Advances in Vaccine Development 
Regardless of why the acellular vaccine confers only short-term immunity, there 
is a clear need to improve upon this vaccine. There is somewhat of a disadvantage in the 
fact that research has not been focused on pertussis for a long time since the problem was 
long thought to be solved effectively by the acellular vaccine. However, there have been 
several new methods and advances in vaccine development and antigen design since 
acellular vaccine was first distributed in the early 1990’s. These methods will be 
discussed in their previous application to other diseases for which vaccine formulation is 
not straightforward. 
Epitope Mapping 
Sometimes it is desirable to work backwards from a known highly potent 
antibody to determine the corresponding epitope, or where on the antigen it will bind. 
Similar to the acellular or subunit approach discussed earlier, it makes intuitive sense that 
reducing vaccine formulations to contain only the desired epitope would focus the 
immune response even further on the crucial parts of the antigen that are most effective at 
neutralization, speeding up clearance of the disease. Epitopes can either be linear 
sequences of amino acids modeled as a single peptide or discontinuous conformational 
parts of the antigen that are brought closely together in the native state.  
 Given the critical importance of epitopes, it is not surprising that there are a 
variety of methods that have been developed in order to find them and characterize their 
interactions with antibodies. One of the first ways used to do this was via “pepscans,” an 
assay introduced by Mario Geysen in 1984 that essentially screened for simple linear 
epitope sequences using an array of peptides assessed by binding. The binding of these 
peptides would then reveal the important sequence of this epitope and could be tested for 
immunogenicity.14  
The problem is that many important epitopes depend on the antigen’s 
conformation and folded structure, not just a linear sequence of amino acids. The two 
main biophysical methods used for these epitopes would be X-ray crystallography and 
nuclear magnetic resonance (NMR). Crystallization is by far the most rigorous assay, 
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utilizing x-ray diffraction of the crystal structure of an antibody bound to the antigen. 
Using the data acquired, the electron densities of the amino acids in a 3D structure can be 
precisely mapped, indicating where the interface is between the antibody and antigen.15 
The major hurdle with this method is that it is very complicated in execution compared to 
other methods and the success rate is fairly low, in part because it is a challenge to 
crystallize the antibody and antigen. In contrast, NMR is used to analyze solutions 
containing these complexes by measuring the changes in electromagnetic radiation 
absorption and emission under an applied magnetic field.15 It has similar disadavantages 
to X-ray crystallography, and it is limited to the analysis of proteins 30 kDa or smaller. 
Both of these methods are good at defining the interface between antigen and antibody, 
but there may be some disagreement between the two assays about which residues play 
an important role at the interface. For the cases where it is difficult to analyze the 
antigen-antibody complex, one can use crystal structures of the individual antigen and 
corresponding antibody to examine computationally how they fit together in a computer. 
However, there are also many limitations to this since the target antigen should be rigid 
(which is characteristic of small molecules), and even then the predicted interface may 
not closely match what happens in nature. 
Another set of assays used to determine the important epitopes can be categorized 
as functional binding assays, which would include ELISAs, dot blots, and Western blots. 
The idea is to use certain parts of the antigen to test for binding so that the important 
epitopes are found by antibody binding to smaller and smaller fragments. One of the 
ways in which this is done is through site-directed mutagenesis, where amino acid 
residues are altered randomly or systematically, and the effects on binding are measured. 
Systematic mutations can be done via alanine scanning, where residues are replaced with 
alanine one at a time.16 This method can be a time-consuming task due to the sheer 
number of mutants that must be synthesized, purified, and characterized for comparison. 
One of the interesting insights that came from this assay was that the manipulation of 
residues outside of the interfacial contact area between antigens and antibodies could 
have more of an impact on binding than those at the interface. The concept that 
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preserving overall epitope structure may sometimes be more important than the residues 
in direct contact with the antibody forms the basis behind structural vaccinology, a novel 
method that is discussed later in this report. 
 The other major method of searching for these epitopes is by using a 
combinatorial approach with phage display peptide libraries. Large numbers of short 
random peptides can be displayed on the phage surface and screened for affinity to an 
immobilized antibody. The DNA contained within the phages that bind can then be 
sequenced to determine the epitope.15 If this technique is used repeatedly until the phage 
that binds most effectively is left, then it can be used as a possible candidate for vaccines. 
Alternatively, it could be attempted to use computational algorithms to find where the 
peptides that bind could correspond to the epitope. 
T-cell Epitopes 
Unlike B-cell epitopes, T-cell epitopes are typically linear and not dependent on 
conformational structure. They are presented on the surface of antigen presenting cells 
(APCs), stimulating an immune response when bound by major histocompatibility 
(MHC) molecules. Since T-cell epitopes are relatively easier to work with, several 
methods have been developed to characterize and modify them.  
One way in which T-cell epitopes have been employed is by increasing the 
immune response. In one example involving an anthrax vaccine candidate, Oscherwitz et 
al. had previously found that a specific B-cell epitope (the loop-neutralizing determinant, 
or LND) located on the 2B2-2B3 loop of protective antigen stimulated high immune 
responses.17 However, some of the rabbit models showed no response at all, and it was 
hypothesized that this was due to the lack of a T-cell epitope contained in the sequence, 
limiting the ability of MHC-II to recognize the antigen. However, when the LND was 
synthesized with the P30 T-cell helper epitope of tetanus toxin, this variant consistently 
neutralized lethal toxin in mice at a higher antibody titer and higher affinity than LND 
without this epitope. 
It may also be desired to decrease the immunogenicity of certain proteins while 
not affecting functionality. This can involve dramatic changes in the T-cell epitopes that 
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may not be possible to discover with conventional methods. In one case, the enzyme used 
to treat childhood acute lymphoblastic leukemia, Escherichia coli L-asparaginase II 
(EcAII), is highly immunogenic, a problem that plagues many heterologous enzymes that 
could be used to treat cancer and other diseases. Cantor et al. were successful in using a 
computational approach to identify T-cell epitopes to test by randomizing the important 
residues with saturation mutagenesis followed by a neutral drift screen so that the enzyme 
changed under selective conditions but did not lose functionality.18 Finally, 
immunogenicity and epitope recognition are tested by antibody titer and T-cell activation 
assays. 
Multiple Epitopes and Truncated Variants 
Another way that vaccine development is complicated with regard to epitopes 
occurs when different strains of the same microbial species have slightly different 
epitopes for the same antigen or have multiple antigens/toxic products that must be 
targeted for an appropriate immune response, making it difficult to produce a single 
vaccine that would be effective at providing protection on a global scale. This problem of 
having multiple epitopes for the same antigen is particularly relevant to lyme disease, 
which is caused by bacteria (belonging to the Borrelia genus) carried in ticks. The outer 
surface protein A (OspA) has been successfully used as an antigen in vaccines for lyme 
disease in the US, where only Borrelia burgdorferi is prevalent. However, this protein 
has many distinct epitopes that vary across the many genetically diverse Borrelia species 
that are prevalent in Europe and Asia. Current research efforts have attempted to 
circumvent this problem entirely by making three recombinant OspA proteins, each of 
which contains protective epitopes for two distinct serotypes. These chimeric molecules 
are fusions of the proximal and distal portions of the OspA sequences that preserve the 
native three-dimensional structure, and they were expressed in Escherichia coli with a T7 
expression system.19 An example of one of these recombinant antigens is shown below in 
Figure 2. Experiments in mice and human clinical trials demonstrate great potential for 
vaccines with these three antigens to provide universal protection across the six different 
serotypes. 
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Figure 2 – Recombinant OspA.19 
Decoy Epitopes 
While using immunogenic, nontoxic antigens as vaccine components is an 
appealing strategy, it is important to note that this approach is only effective if the 
functionally important parts or epitopes of the antigens are recognized by the immune 
system. The problem is that it is not always easy to choose the right epitope, and the 
immune system may preferentially recognize a different epitope based on accessibility 
and abundance. This issue is what makes vaccine development so difficult, particularly in 
the case of viruses that use decoy epitopes on structural proteins that effectively “hide” 
the toxic protein and/or viral DNA until it has already invaded the cell. 
For example, HIV utilizes highly variable regions on the outer envelope protein 
that are immunodominant but do not ultimately impair the ability of the viral DNA to 
invade and replicate inside host cells. Likewise, influenza virus uses surface 
hemagglutinin (HA) to bind and enter cells, but epitopes near HA’s receptor binding site 
are highly variable. This problem is further exacerbated by antigenic drift, which are 
mutations that accumulate slowly over time, and antigenic shift, which is when viruses 
affecting the same host can exchange segments of RNA in an event similar to crossing 
over that results in mutant versions of HA for which humans have no pre-existing 
immunity.  
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Reverse Vaccinology 
Reverse vaccinology, a concept developed in 2000 by Rino Rappuoli, is the 
process of using bioinformatics to screen the entire pathogenic genome for suitable 
vaccine candidates. The traditional process of growing up bacterial cultures, isolating 
antigens, and testing them with biochemical assays and in animal models can be costly, 
time consuming, and is limited by only focusing on proteins that are highly immunogenic 
but do not necessarily result in protective immunity for the reasons discussed previously. 
Reverse vaccinology counteracts these issues by being able to look at virtually every 
possible antigen contained in the bacterial genome, avoiding the inherent bias of 
immunogenicity or ability to generate large quantities of the antigen in a laboratory 
setting. 
One of the very first examples of success using this method was in the 
development of a new vaccine for serotype B Neisseria meningitidis, which can cause 
meningitis by crossing the blood-brain barrier, evading the immune system in a 
polysaccharide capsule. For most serotypes (A, C, Y, and W135), vaccines designed to 
enlist bactericidal antibodies to attack the capsule are effective, but the capsule for 
serotype B is a special case since it is identical in composition to the polysialic acid 
present in human glycoproteins, eluding an immune response as a human self-antigen and 
making it difficult to apply traditional techniques to find protective epitopes. Reverse 
vaccinology came into play by using bioinformatics analysis of the entire bacterial 
genome to predict which of the total 2158 proteins were exposed on the surface or 
secreted to the extracellular milieu.20 About 350 of these antigens were then expressed 
and purified from E. coli cultures and tested in mice. Serum samples from these mice 
were then be tested for protection via a bactericidal assay, leading to five previously 
undiscovered vaccine candidates that were combined in a formulation known as 
4CMenB, which just completed clinical trials.21 
What if there are several bacterial strains with no viable universal vaccine 
candidate? Such was the case with Group B streptococcus. Using reverse vaccinology by 
sequencing eight bacterial genomes representative of this strain, it was found that about 
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589 genes were predicted to be proteins expressed on the surface, and ultimately four of 
them showed evidence of protection in an animal model.22 However, none of the four 
antigens would have been detected through the use of traditional methods to find a 
universal candidate for all of the strains; three of them were not expressed in all eight 
genomes, and the one protein that was expressed in all of the genomes was not exposed 
on the surface for all of the strains. This scenario in particular highlights the need to 
screen multiple genomes that not only express antigens of interest but also take into 
account the variation in surface availability and expression levels. 
Structural Vaccinology 
Another new approach that is starting to show promise in vaccine development is 
structural vaccinology. Rather than focusing on the sequences of important epitopes, this 
method places more importance on preserving the core structure of the antigen so that the 
folding of the overall epitope is preserved. This can also be used in conjunction with 
reverse vaccinology once suitable epitopes have been found, as depicted in Figure 3 
below. There are several cases already for which this method has been used successfully.  
 
Figure 3 – Reverse Vaccinology and Structural Vaccinology.23 
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As described before, the surface-exposed factor H-binding protein (fHbp) has 
been identified by reverse vaccinology as a highly immunogenic antigen, but there are 
over 500 different variants that can be classified into three main groups that do not elicit 
cross-protection for each other. This implies that any effective vaccine would require at 
least three antigens in the formulation, making production complicated and expensive 
when compared to the ideal case of a single antigen. The first attempt to make a single 
universal antigen was to insert amino acid sequences from the other variants into the gene 
for variant 1, but the failure of this approach suggested that the 3D structures of each 
epitope would also need to be preserved for protection. By dividing the 1 C terminus into 
separate patches large enough (900 to 2000 A) to preserve epitope structure while 
inserting key amino acid sequences where they would be most exposed to the solvent, an 
antigen was made that generated antibodies to all three variants.24  
 
 
 
Figure 4 – Structural Vaccinology Strategy with fHbp.24 
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In other cases, this approach has shown that antigens mirroring specific structural 
domains of proteins may be all that is required to elicit an effective immune response that 
is broadly protective, as was the case for the BP-2a backbone protein variant of Group B 
streptococcus (GBS).25 Due to the reverse vaccinology work discussed previously, it was 
revealed that all GBS strains express pili, structures composed of a backbone protein and 
two ancillary proteins. The backbone component has been shown to be protective, but its 
selection as an antigen is complicated by the eight different variants that are possible. 
However, the 3D structure for the six variants corresponding to one of the three genomic 
pilus islands (BP-2a) showed that the backbone was organized into four domains (D1 
through D4), of which D3 was primarily exposed for binding and triggered 
opsonophagocytotic antibodies. It was later shown that the D3 domains of each variant, 
when combined into one recombinant antigen, were enough to induce protection from all 
six variants of BP-2a.25 
Another important example is in the formulation of a vaccine for respiratory 
syncytial virus (RSV) that is now in the clinical trial phase. Some structural studies have 
shown that targeting the fusion (F) glycoprotein would be ideal. However, the problem is 
that this protein undergoes changes in conformation (from a pre-fusion form to a transient 
intermediate to a post-fusion form) during invasion of host cells. Since protection is 
mainly hypothesized to come from the prevention of invasion into host cells, it makes 
intuitive sense that the initial conformation of the F glycoprotein would be the desired 
one to target. Unfortunately, this conformation is difficult to isolate since extraction by 
detergent and other methods makes it quickly shift to the post-fusion form. Using 
previous experience with the engineering of the HPIV-3 post-fusion protein, researchers 
modified the post-fusion F glycoprotein of RSV by manipulating the fusion protein 
region to simultaneously reduce hydrophobicity, increase thermostability, and increase 
homogeneity.26 These properties are highly desired for antigens since they must be 
hydrophilic for purification, stable enough for a long shelf life, and able to crystallize for 
ease of characterization. It was unexpected for this antigen to be as efficient at 
neutralization since it was expected that the epitopes on the antigen surface would be 
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folded differently and buried inside the pre-fusion conformer. The crystal structure of the 
engineered F glycoprotein revealed that an alpha helix insertion had caused the protective 
epitopes to be exposed, and that these epitopes were largely unaffected by the switch 
between the pre-fusion and post-fusion structures.24 
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Conclusion 
Given the information presented here, it is clear that there are many factors to take 
into consideration when selecting and designing antigens for a particular pathogen. For 
the most challenging infectious diseases, it is no longer sufficient to blindly screen for 
antigens that are the most immunogenic. In order to generate an appropriate immune 
response, future antigens must be assessed by strategically screening the genomic 
information for potential protective antigens, examining the epitopes that are available, 
and preserving the crucial structures required for immunogenicity.  
There are many new promising approaches that take advantage of the recent 
strides made in high throughput screening and genomic research. Reverse and structural 
vaccinology have already been shown to be successful at making progress in discovering 
suitable vaccine candidates that may have been impossible to find or, at the very least, 
difficult and time consuming to search for using traditional techniques. It will become 
increasingly crucial to determine how to leverage the vast amount of genomic 
information from multiple strains to formulate universal vaccines with antigens that 
stimulate broad protection in disease variants on a global scale, making them more 
economical and effective. 
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